ADArtem A. Derkaev

Artem A. Derkaev

*This is an algorithmically generated author record based on publicly available information.

Artem A. Derkaev has a total of 62 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Development and scaling of a chromatographic purification technology for single-domain antibodies fused to the Fc fragment of human IgG1

    by D. S. Polyansky, V. V. Prokofiev, A. V. Samorukova, F. A. Shishkonakov, D. V. Vasiliev, E. I. Ryabova, A. A. Derkaev, A. I. Gosudarev, Yu. А. Efimova, D. V. Shcheblyakov, et al.

    Objectives. The work set out to develop a chromatographic purification technology for drugs based on modified single-domain antibodies specific to the SARS-CoV-2 virus, as well as to select the optimal parameters for the purification process and scale up this technology for production. Methods. The study was conducted on a culture of Chinese hamster ovary (CHO) cells GAMP2C5 clone 78, CHO B5 clone 4, and CHO B10 clone 4, which were used to produce modified single-domain antibodies GAMP2C5, GAMB5, and GAMB10, respectively. Chromatographic purification was performed using AKTA pure 25 and AKTA Pilot 600s chromatographs. Quality control of the obtained drugs was carried out using high-performance liquid chromatography, capillary gel electrophoresis, dynamic light scattering, enzymelinked immunosorbent assay, and polymerase chain reaction. Results. Multimodal chromatography using CA ++ Pure-HA ( TOSOH , Japan) resin based on type 1 ceramic hydroxyapatite can be effectively used for the removal of aggregated antibody forms. The drugs obtained after chromatography using CA ++ Pure-HA resin based on type 1 ceramic hydroxyapatite have a purity of more than 97%. The developed purification technology was scaled up to purify 200 L of culture fluid after cultivation in an STR 200 bioreactor. Conclusions. The described technology developed for purifying modified mono-domain antibodies using the CA ++ Pure-HA multimodal resin based on type 1 ceramic hydroxyapatite allows for the effective removal of low-molecular-weight impurities and aggregated forms of the antibody. The antibodies obtained using the developed technology are characterized by a high degree of purity and the absence of various impurities (residual protein of the producer strain, residual protein A, and residual DNA of the producer strain), as well as offering a hydrodynamic molecular radius corresponding to the theoretical value of monomeric forms of antibodies.

  • Open Access

    Comparative analysis of three genetic constructs for delivery and expression of a modified single-domain antibody gene in rAAV

    by E. I. Ryabova, A. A. Derkaev, I. B. Esmagambetov, M. A. Dovgiy, A. A. Blinov, R. M. Hossain, O. E. Dmitriev, D. S. Polyansky, A. N. Noskov, D. V. Shcheblyakov, et al.

    Objectives. To obtain and compare the efficiency of three recombinant adeno-associated virus (rAAV) variants expressing the gene of the modified single-domain antibody B11-Fc specific to botulinum toxin type A (BoNT/A): rAAV-DJ-CMV-B11-Fc, rAAV-DJ-CASI-B11-Fc, and scAAV-DJ-CMV-B11-Fc. Methods. The AAV-DJ Packaging System ( Cell Biolabs , USA) was used to create target constructs and obtain rAAV. Expression of the B11-Fc antibody gene in the obtained rAAV was assessed in vitro (HEK293, CHO-S, and C2C12 cell lines) and in vivo (BALB/c mice) using biolayer interferometry. The protective properties of the drugs were investigated on the model of lethal intoxication of mice with BoNT/A. Results. The rAAV-DJ-CMV-B11-Fc drug demonstrated a high level of B11-Fc antibody production both in vitro and in vivo without a significant decrease in concentration for at least 6 months. Comparable levels of B11-Fc production were demonstrated by rAAV-DJ-CASI-B11-Fc and scAAV-DJ-CMV-B11-Fc drugs in both in vitro and in vivo studies, with the exception of C2C12 cells, where rAAV-DJ-CASI-B11-Fc demonstrated the highest efficacy. When investigating the protective activity of the drugs against a lethal dose of BoNT/A, it was found that rAAV-DJ-CASI-B11-Fc possessed more pronounced activity in the first two days following administration as compared to rAAV-DJ-CMV-B11-Fc. However, at later stages, starting from 3 months, the rAAV-DJ-CMV-B11-Fc drug product demonstrated the most pronounced protection against high doses of BoNT/A. Conclusions. The obtained data show that rAAV-DJ-CASI-B11-Fc should be used for the induction of protection against BoNT/A at early stages (24–48 h) after administration, whereas for protection against the highest doses of BoNT/A in the long term, rAAV-DJ-CMV-B11-Fc should be used. Studies into the specific activity of the drugs at later stages after administration are still ongoing.


  • Open Access

    A modified single-domain antibody candidate for the treatment of botulism caused by botulinum toxin type A

    by A. A. Derkaev, E. I. Ryabova, I. B. Esmagambetov, D. V. Shcheblyakov, A. N. Noskov, I. D. Vinogradova, V. V. Prokofiev, D. S. Polyansky, D. Y. Logunov, A. L. Gintsburg

    INTRODUCTION. Currently, the primary treatment method for botulism is the use of botulinum antitoxin, which causes a number of side effects, including allergic reactions. The development of medicinal products based on monoclonal antibodies (mAbs), in particular, single-domain mAbs fused to the human IgG1 Fc fragment, holds promise for the treatment of botulinum toxin poisoning.AIM. This study aimed to optimise the technology for laboratory-scale production of a single-domain mAb fused to the human IgG1 Fc fragment (B11-Fc) for botulism treatment and post-exposure prophylaxis and to conduct a preclinical efficacy study of this mAb.MATERIALS AND METHODS. The study used CHO cells. B7, a stable clone producing the B11-Fc single-domain mAb, was cultured in Erlenmeyer flasks using commercially available media and feeds. The B11-Fc mAb was purified using multistep chromatography (including affinity, anion exchange, and multimodal chromatography steps), virus elimination, and tangential flow filtration. The purity of the B11-Fc mAb was assessed by high-performance liquid chromatography (HPLC) and electrophoresis. The glycan profile was established by HPLC. Bio-layer interferometry was used to measure the mAb concentration in the culture fluid and to determine the equilibrium dissociation constants for the mAb and various Fc receptors. Botulinum toxin type A (BoNT/A) was produced by culturing the Clostridium botulinum A98 strain and purified by chromatography. In vivo experiments involved intraperitoneal and intragastric administration of BoNT/A to female BALB/c mice, with a subsequent assessment of the severity of toxic signs. The B11-Fc mAb was administered intramuscularly or intravenously (to study the pharmacokinetics). The efficacy of the B11-Fc mAb (in terms of mouse survival) was studied using various toxicity models and the prophylactic and therapeutic modes of administration.RESULTS. The study optimised culture conditions for the B11-Fc mAb producer clone and developed a mAb purification technology that ensured a high yield (0.5 g/L) and a purity of over 99%. The average particle size in the mAb preparation was 7.85 nm. The study characterised the glycan profile of the B11-Fc mAb and determined the equilibrium dissociation constants for the mAb and human Fc receptors. Poisoning with BoNT/A was modelled in mice. The intramuscular administration of the B11-Fc mAb at a dose of 0.6 mg/kg provided 100% protection from poisoning with BoNT/A that was simultaneously administered at a dose of 20 LD50. The study determined the main pharmacokinetic parameters of the B11-Fc mAb. The experiments demonstrated that prophylactic administration of the B11-Fc mAb for 21 days had a protective effect against BoNT/A administered intraperitoneally at a dose of 5 LD50, and therapeutic administration of the mAb 14 h after intragastric administration of the toxin at a dose of 12,000 intraperitoneal LD50 provided 100% protection.CONCLUSIONS. The authors optimised the technology for laboratory-scale production of the candidate modified single-domain mAb. In vivo experiments conducted using BoNT/A toxicity models demonstrated that the B11-Fc mAb is highly effective in botulism prevention and treatment. On the basis of preclinical data, phase I clinical trials have been initiated to study B11-Fc in healthy volunteers.


  • Open Access

    Development of technology for culturing a cell line producing a single-domain antibody fused with the Fc fragment of human IgG1

    by D. S. Polyansky, E. I. Ryabova, A. A. Derkaev, N. S. Starkov, I. S. Kashapova, D. V. Shcheblyakov, A. P. Karpov, I. B. Esmagambetov

    Objectives. To develop an effective technology for the cultivation of Chinese hamster ovary (CHO) cells stably producing GamP2C5 antibody which is a component I of the GamCoviMab candidate drug for emergency prevention and therapy of infection caused by SARS-CoV-2 virus; to select optimal cultivation parameters and to scale this technology in production.Methods. The study was performed on CHO GamP2C5 (clone 78) cell culture, producing a single-domain antibody fused to the Fc fragment of human IgG1 GamP2C5. Different culture media and supplements were used. Cells were cultured in Erlenmeyer flasks, Biostat® RM 20 wave-mixed bioreactor, Ambr® 250 mini bioreactors, STR 200 stirred-tank bioreactor.Results. Using molecular-genetic and biotechnological methods, a stable clone producer of CHO GamP2C5 antibody, clone 78, was obtained. Then a technique was worked out for the cultivation of the obtained clone producer on different culture media. The most suitable cultivation regimes, culture media, and optimal supplements were selected. This technology was tested in laboratory conditions in a 10-L reactor, and then successfully scaled up for production at the MedGamal Branch of the Gamaleya National Research Center for Epidemiology and Microbiology.Conclusions. This study demonstrates the fundamental feasibility of developing and scaling up a culture technology, in order to produce a drug based on a modified single-domain antibody with virus neutralizing activity against different strains of SARS-CoV-2 virus.


  • Use of recombinant adeno-associated virus for passive immunization and protection against infectious diseases

    by E.I. Ryabova, A.A. Derkaev, N.V. Pimenov, I.B. Esmagambetov

    Infectious diseases remain a serious problem that requires constant improvement of effective methods of therapy and prevention. Traditional vaccination methods provide a durable immune response, but require time to produce antibodies. Passive immunization using antibodies provides immediate protection, but is limited to a short period of antibody circulation in the body. Recombinant adeno-associated viral vector (rAAV) has low immunogenicity and the ability for prolonged gene expression in host cells, which ensures the induction of persistent immune protection and overcomes the limitations of other methods. These properties make it a promising platform for passive immunization and long-term protection against infectious agents. The use of rAAVs, which carry genes for specific neutralizing antibodies to protect against viral diseases such as influenza, coronaviruses and HIV, demonstrate high efficacy and safety in preclinical and clinical studies. The first phases of clinical trials of rAAV drugs for the prevention and treatment of HIV infection showed their safety and good tolerability. Also, the expression of monoclonal antibodies specific to bacterial exotoxins (enterotoxin A, cytotoxin B, botulinum toxin A, etc.) in rAAV can be used to treat the corresponding bacterial infections (clostridia, botulism, etc.). This review examines current research using rAAV as an innovative strategy for the delivery and expression of genes encoding neutralizing antibodies to provide long-term protection against infectious diseases. A review of the above studies highlights the significance and promise of the use of rAAV in the fight against infectious diseases, and also points to the prospects for further research in this area.

  • The Use of Recombinant Adeno-Associated Virus for Passive Immunization and Protection against Infectious Diseases

    by E. I. Ryabova, A. A. Derkaev, N. V. Pimenov, I. B. Esmagambetov

    Infectious diseases remain a serious problem that requires constant improvement of effective methods of therapy and prevention. Traditional vaccination met

  • Open Access

    Production and characterisation of a SARS-CoV-2 S-protein RBD homodimer with increased avidity for specific antibodies

    by A. A. Derkaev, E. I. Ryabova, V. V. Prokofiev, I. A. Favorskaya, D. M. Grousova, I. B. Esmagambetov, I. V. Dolzhikova, D. V. Shcheblyakov

    Monitoring of the proportion of immune individuals and the effectiveness of vaccination in a population involves evaluation of several important parameters, including the level of virus-neutralising antibodies. In order to combat the COVID-19 pandemic, it is essential to develop approaches to detecting SARS-CoV-2 neutralising antibodies by safe, simple and rapid methods that do not require live viruses. To develop a test system for enzyme-linked immunosorbent assay (ELISA) that detects potential neutralising antibodies, it is necessary to obtain a highly purified recombinant receptor-binding domain (RBD) of the spike (S) protein with high avidity for specific antibodies.The aim of the study was to obtain and characterise a SARS-CoV-2 S-protein RBD homodimer and a recombinant RBD-expressing cell line, as well as to create an ELISA system for detecting potential neutralising antibodies.Materials and methods: the genetic construct was designed in silico. To generate a stable producer cell line, the authors transfected CHO-S cells, subjected them to antibiotic pressure, and selected the optimal clone. To isolate monomeric and homodimeric RBD forms, the authors purified the recombinant RBD by chromatographic methods. Further, they analysed the activity of the RBD forms by Western blotting, bio-layer interferometry, and indirect ELISA. The analysis involved mono clonal antibodies GamXRH19, GamP2C5, and h6g3, as well as serum samples from volunteers vaccinated with Gam-COVID-Vac (Sputnik V) and unvaccinated ones.Results: the authors produced the CHO-S cell line for stable expression of the recombinant SARS-CoV-2 S-protein RBD. The study demonstrated the recombinant RBD’s ability to homodimerise after fed-batch cultivation of the cell line for more than 7 days due to the presence of unpaired cysteines. The purified recombinant RBD yield from culture broth was 30–50 mg/L. Monomeric and homodimeric RBD forms were separated using gel-filtration chromatography and characterised by their ability to interact with specific monoclonal antibodies, as well as with serum samples from vaccinated volunteers. The homodimeric recombinant RBD showed increased avidity for both monoclonal and immune sera antibodies.Conclusions: the homodimeric recombinant RBD may be more preferable for the analysis of levels of antibodies to the receptor-binding domain of the SARS-CoV-2 S protein.


  • Open Access

    Single-domain antibody delivery using an mRNA platform protects against lethal doses of botulinum neurotoxin A

    by Eugenia A. Panova, Denis A. Kleymenov, Dmitry V. Shcheblyakov, Evgeniia N. Bykonia, Elena P. Mazunina, Alina S. Dzharullaeva, Anastasia N. Zolotar, Artem A. Derkaev, Ilias B. Esmagambetov, Ivan I. Sorokin, et al.

    Single-domain antibodies (sdAbs, VHHs, or nanobodies) are a promising tool for the treatment of both infectious and somatic diseases. Their small size greatly simplifies any genetic engineering manipulations. Such antibodies have the ability to bind hard-to-reach antigenic epitopes through long parts of the variable chains, the third complementarity-determining regions (CDR3s). VHH fusion with the canonical immunoglobulin Fc fragment allows the Fc-fusion single-domain antibodies (VHH-Fc) to significantly increase their neutralizing activity and serum half-life. Previously we have developed and characterized VHH-Fc specific to botulinum neurotoxin A (BoNT/A), that showed a 1000-fold higher protective activity than monomeric form when challenged with five times the lethal dose (5 LD 50 ) of BoNT/A. During the COVID-19 pandemic, mRNA vaccines based on lipid nanoparticles (LNP) as a delivery system have become an important translational technology that has significantly accelerated the clinical introduction of mRNA platforms. We have developed an mRNA platform that provides long-term expression after both intramuscular and intravenous application. The platform has been extensively characterized using firefly luciferase (Fluc) as a reporter. An intramuscular administration of LNP-mRNA encoding VHH-Fc antibody made it possible to achieve its rapid expression in mice and resulted in 100% protection when challenged with up to 100 LD 50 of BoNT/A. The presented approach for the delivery of sdAbs using mRNA technology greatly simplifies drug development for antibody therapy and can be used for emergency prophylaxis.

  • Open Access

    Nanobodies Are Potential Therapeutic Agents for the Ebola Virus Infection

    by Ilias B. Esmagambetov, Dmitriy V. Shcheblyakov, Daria A. Egorova, Olga L. Voronina, Artem A. Derkaev, Daria V. Voronina, Olga Popova, Ekaterina I. Ryabova, Ekaterina I. Aksenova, Andrey N. Semenov, et al.

    Ebola fever is an acute, highly contagious viral disease with a mortality rate that can reach 90%. There are currently no licensed therapeutic agents specific to Ebola in the world. Monoclonal antibodies (MAbs) with viral-neutralizing activity and high specificity to the Ebola virus glycoprotein (EBOV GP) are considered as highly effective potential antiviral drugs. Over the past decade, nanobodies (single-domain antibodies, non-canonical camelid antibodies) have found wide use in the diagnosis and treatment of various infectious and non-infectious diseases. In this study, a panel of nanobodies specifically binding to EBOV GP was obtained using recombinant human adenovirus 5, expressing GP (Ad5-GP) for alpaca (Vicugna pacos) immunization, for the first time. Based on specific activity assay results, affinity constants, and the virus-neutralizing activity against the recombinant vesicular stomatitis virus pseudotyped with EBOV GP (rVSV-GP), the most promising clone (aEv6) was selected. The aEv6 clone was then modified with the human IgG1 Fc fragment to improve its pharmacokinetic and immunologic properties. To assess the protective activity of the chimeric molecule aEv6Fc, a lethal model of murine rVSV-GP infection was developed by using immunosuppression. The results obtained in lethal model mice have demonstrated the protective effect of aEv6Fc. Thus, the nanobody and its modified derivative obtained in this study have shown potential protective value against Ebola virus.


  • Open Access

    Single-domain antibodies efficiently neutralize SARS-CoV-2 variants of concern, including Omicron variant

    by Irina A. Favorskaya, Dmitry V. Shcheblyakov, Ilias B. Esmagambetov, Inna V. Dolzhikova, Irina A. Alekseeva, Anastasia I. Korobkova, Daria V. Voronina, Ekaterina I. Ryabova, Artem A. Derkaev, Anna V. Kovyrshina, et al.

    Virus-neutralizing antibodies are one of the few treatment options for COVID-19. The evolution of SARS-CoV-2 virus has led to the emergence of virus variants with reduced sensitivity to some antibody-based therapies. The development of potent antibodies with a broad spectrum of neutralizing activity is urgently needed. Here we isolated a panel of single-domain antibodies that specifically bind to the receptor-binding domain of SARS-CoV-2 S glycoprotein. Three of the selected antibodies exhibiting most robust neutralization potency were used to generate dimeric molecules. We observed that these modifications resulted in up to a 200-fold increase in neutralizing activity. The most potent heterodimeric molecule efficiently neutralized each of SARS-CoV-2 variant of concern, including Alpha, Beta, Gamma, Delta and Omicron variants. This heterodimeric molecule could be a promising drug candidate for a treatment for COVID-19 caused by virus variants of concern.